Citations

Clear

6273 citation(s) found for "To, Andrew".

DIPG-21. EVALUATING THERAPEUTIC VULNERABILITIES IN DIPG USING AURORA KINASE INHIBITOR AS A NOVEL THERAPY
Zhang, Liang , Bender, Andrew T. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | June 21, 2018 | Volume: 20 | Issue: suppl_2 | Pages: i53-i53

10.1093/neuonc/noy059.114 Get It

Lower Fasted‐State but Greater Increase in Muscle Protein Synthesis in Response to Elevated Plasma Amino Acids in Obesity
Tran, Lee , Kras, Katon A., Hoffman, Nyssa, Ravichandran, Jayachandran , Dickinson, Jared M. , D’Lugos, Andrew C. , Carroll, Chad C. , Patel, Shivam H. , Mandarino, Lawrence J. , Roust, Lori R., Katsanos, Christos S. , Katsanos, Christos S , D'Lugos, Andrew C

Mayo Clinic

Obesity | June 13, 2018 | Volume: 26 | Issue: 7 | Pages: 1179-1187

10.1002/oby.22213 | PMID 29896930 Get It

ObjectiveObesity alters protein metabolism in skeletal muscle, but consistent evidence is lacking. This study compared muscle protein synthesis in adults with obesity and in lean controls in the fasted state and during an amino acid infusion.MethodsTen subjects with obesity (age: 36 ± 3 years; BMI: 34 ± 1 kg/m2) and ten controls (age: 35 ± 3 years; BMI: 23 ± 1 kg/m2) received an infusion of L‐[2,3,3,4,5,5,5,6,6,6‐2H10]leucine (0.15 μmol/kg fat‐free mass/min) to measure muscle protein synthesis after an overnight fast and during amino acid infusion.ResultsDespite greater muscle mammalian target of rapamycin phosphorylation (P ≤ 0.05), fasted‐state mixed‐muscle and mitochondrial protein synthesis were lower in subjects with obesity (P ≤ 0.05). However, the change in mixed‐muscle protein synthesis during the amino acid infusion was 2.7‐fold greater in subjects with obesity (P ≤ 0.05), accompanied by a greater change in S6 kinase‐1 phosphorylation (P ≤ 0.05). The change in mitochondrial protein synthesis did not differ between groups (P > 0.05).ConclusionsAdults with obesity have reduced muscle protein synthesis in the fasted state, but this response is compensated for by a greater change in overall muscle protein synthesis during amino acid infusion.
Innovative Use of Novel Biomarkers to Improve the Safety of Renally Eliminated and Nephrotoxic Medications
Frazee, Erin N. , Voils, Stacy A. , Kane‐Gill, Sandra L. , Frazee, Erin N , Kane-Gill, Sandra L , Rule, Andrew D.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | June 8, 2018 | Volume: 38 | Issue: 8 | Pages: 794-803

10.1002/phar.2149 | PMID 29883532 Get It

Over the last decade, the discovery of novel renal biomarkers and research on their use to improve medication effectiveness and safety has expanded considerably. Pharmacists are uniquely positioned to leverage this new technology for renal assessment to improve medication dosing and monitoring. Serum cystatin C is a relatively new, inexpensive, functional renal biomarker that responds more quickly to changing renal function than creatinine and is not meaningfully affected by age, sex, skeletal muscle mass, dietary intake, or deconditioning. Cystatin C has been proposed as an adjunct or alternative to creatinine for glomerular filtration rate assessment and estimation of drug clearance. Tissue inhibitor of metalloproteinase‐2·insulin‐like growth factor‐binding protein 7 ([TIMP‐2]·[IGFBP7]) is a composite of two damage biomarkers released into the urine at a checkpoint in mitosis when renal cells undergo stress or sense a future risk of damage. Concentrations of [TIMP‐2]·[IGFBP7] increase before a rise in serum creatinine is evident, thus providing insightful information for evaluation in the context of other patient data to predict the risk for impending kidney injury. This article provides a brief overview of novel renal biomarkers being used as a mechanism to improve medication safety including a discussion of cystatin C, as part of drug‐dosing algorithms and specifically for vancomycin dosing, and the use of [TIMP‐2]·[IGFBP7] for risk prediction in acute kidney injury and drug‐induced kidney disease. Select cases of clinical experience with novel renal biomarkers are outlined, and lessons learned and future applications are described.
Knowledge of endoscopic ultrasound-delivered fiducial composition and dimension necessary when planning proton beam radiotherapy
Gleeson, Fergus , Tryggestad, E., Remmes, Nicholas B. , Beltran, Chris , Kruse, Jon J. , Haddock, Michael G. , Hallemeier, Christopher L. , Storm, Andrew C. , Levy, Michael J. , Tryggestad, Erik J, Beltran, Chris J., Storm, Andrew C , Beltran, Chris J , Hallemeier, Christopher Leigh , Levy, Michael J.

Mayo Clinic

Endoscopy International Open | June 5, 2018 | Volume: 06 | Issue: 06 | Pages: E766-E768

10.1055/a-0588-4800 | PMID 29876514 Get It

Abstract Background and study aims Little consideration has been given to selection of endoscopic ultrasound-guided fiducials for proton radiotherapy and the resulting perturbations in the therapy dose and pattern. Our aim was to assess the impact of perturbations caused by six fiducials of different composition and dimensions in a phantom gel model. Materials and methods The phantom was submerged in a water bath and irradiated with a uniform 10 cm × 10 cm field of 119.7 MeV monoenergetic spot scanning protons delivered through a 45 mm range shifter. The proton “Bragg Peak” was evaluated. Results Dose perturbations manifesting as dose reductions up to 30 % were observed. A carbon composite (1 × 5 mm) and gold (0.4 × 10 mm) fiducial with backload potential rather than dedicated EUS pre-loaded gold fiducial needles had the best performance in terms of minimizing the dose perturbation. Conclusions Our data demonstrate that a carbon composite fiducial has a less untoward effect on proton therapy dose distribution than dedicated EUS pre-loaded gold fiducial needles. Such information is important to consider when selecting fiducials specifically for proton therapy.
Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 90-100

10.1089/humc.2017.142 | PMID 29869540 Get It

Self-Complementary Adeno-Associated Virus–Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 101-112

10.1089/humc.2017.143 | PMID 29869535 Get It